362 related articles for article (PubMed ID: 30965070)
1. Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies.
Wandeler G; Mauron E; Atkinson A; Dufour JF; Kraus D; Reiss P; Peters L; Dabis F; Fehr J; Bernasconi E; van der Valk M; Smit C; Gjærde LK; Rockstroh J; Neau D; Bonnet F; Rauch A;
J Hepatol; 2019 Aug; 71(2):274-280. PubMed ID: 30965070
[TBL] [Abstract][Full Text] [Related]
2. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.
Boyd A; Bottero J; Miailhes P; Lascoux-Combe C; Rougier H; Girard PM; Serfaty L; Lacombe K
J Int AIDS Soc; 2017 Feb; 20(1):21426. PubMed ID: 28362068
[TBL] [Abstract][Full Text] [Related]
3. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection.
Surial B; Ramírez Mena A; Roumet M; Limacher A; Smit C; Leleux O; Mocroft A; van der Valk M; Bonnet F; Peters L; Rockstroh JK; Günthard HF; Berzigotti A; Rauch A; Wandeler G; ; ; ;
J Hepatol; 2023 May; 78(5):947-957. PubMed ID: 36690280
[TBL] [Abstract][Full Text] [Related]
4. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy.
Sarkar J; Saha D; Bandyopadhyay B; Saha B; Chakravarty R; Guha SK
Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414
[TBL] [Abstract][Full Text] [Related]
5. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.
Audsley J; Bent SJ; Littlejohn M; Avihingsanon A; Matthews G; Bowden S; Bayliss J; Luciani F; Yuen L; Fairley CK; Locarnini S; Lewin SR; Sasadeusz J
AIDS; 2016 Jun; 30(10):1597-606. PubMed ID: 26950313
[TBL] [Abstract][Full Text] [Related]
6. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression.
Huang AJ; Núñez M
J Int Assoc Provid AIDS Care; 2015; 14(4):360-8. PubMed ID: 25999329
[TBL] [Abstract][Full Text] [Related]
8. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.
Bihl F; Martinetti G; Wandeler G; Weber R; Ledergeber B; Calmy A; Battegay M; Cavassini M; Vernazza P; Caminada AP; Rickenbach M; Bernasconi E;
BMC Gastroenterol; 2015 Jul; 15():79. PubMed ID: 26152237
[TBL] [Abstract][Full Text] [Related]
9. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study.
Nguyen MH; Yang HI; Le A; Henry L; Nguyen N; Lee MH; Zhang J; Wong C; Wong C; Trinh H
J Infect Dis; 2019 Jan; 219(1):10-18. PubMed ID: 29982737
[TBL] [Abstract][Full Text] [Related]
10. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
Kim WR; Loomba R; Berg T; Aguilar Schall RE; Yee LJ; Dinh PV; Flaherty JF; Martins EB; Therneau TM; Jacobson I; Fung S; Gurel S; Buti M; Marcellin P
Cancer; 2015 Oct; 121(20):3631-8. PubMed ID: 26177866
[TBL] [Abstract][Full Text] [Related]
11. Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.
Lewin SR; Ribeiro RM; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini SA; Ruxrungtham K; Perelson AS; Dore GJ
Hepatology; 2009 Apr; 49(4):1113-21. PubMed ID: 19115219
[TBL] [Abstract][Full Text] [Related]
12. Incidence of hepatocellular carcinoma in patients with chronic liver disease due to hepatitis B or C and coinfected with the human immunodeficiency virus: A retrospective cohort study.
Marcon PDS; Tovo CV; Kliemann DA; Fisch P; de Mattos AA
World J Gastroenterol; 2018 Feb; 24(5):613-622. PubMed ID: 29434450
[TBL] [Abstract][Full Text] [Related]
13. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
[TBL] [Abstract][Full Text] [Related]
14. Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia.
Vinikoor MJ; Sinkala E; Chilengi R; Mulenga LB; Chi BH; Zyambo Z; Hoffmann CJ; Saag MS; Davies MA; Egger M; Wandeler G;
Clin Infect Dis; 2017 May; 64(10):1343-1349. PubMed ID: 28158504
[TBL] [Abstract][Full Text] [Related]
15. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
[TBL] [Abstract][Full Text] [Related]
16. Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL.
Li Y; Xie J; Han Y; Wang H; Zhu T; Wang N; Lv W; Guo F; Qiu Z; Li Y; Du S; Song X; Thio CL; Li T
J Acquir Immune Defic Syndr; 2016 May; 72(1):39-45. PubMed ID: 26745828
[TBL] [Abstract][Full Text] [Related]
17. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015.
Sun J; Althoff KN; Jing Y; Horberg MA; Buchacz K; Gill MJ; Justice AC; Rabkin CS; Goedert JJ; Sigel K; Cachay E; Park L; Lim JK; Kim HN; Lo Re V; Moore R; Sterling T; Peters MG; Achenbach CJ; Silverberg M; Thorne JE; Mayor AM; Crane HM; Kitahata MM; Klein M; Kirk GD;
JAMA Netw Open; 2021 Feb; 4(2):e2037512. PubMed ID: 33595662
[TBL] [Abstract][Full Text] [Related]
18. Brief Report: Relationship Between ABCC4 SNPs and Hepatitis B Virus Suppression During Tenofovir-Containing Antiretroviral Therapy in Patients With HIV/HBV Coinfection.
Archampong T; Ojewale O; Bears K; Chen Y; Lartey M; Sagoe KW; Obo-Akwa A; Gong Y; Langaee T; Kwara A
J Acquir Immune Defic Syndr; 2019 Dec; 82(4):421-425. PubMed ID: 31335591
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir disoproxil fumarate on the risk of hepatocellular carcinoma in chronic hepatitis B patients with failure to preceding treatments: A nationwide cohort study.
Lee J; Kim GA; Kim HJ; Cho S; Ko MJ; Lim YS
J Viral Hepat; 2021 Aug; 28(8):1150-1159. PubMed ID: 33934466
[TBL] [Abstract][Full Text] [Related]
20. Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection.
Huang YS; Chang SY; Sheng WH; Sun HY; Lee KY; Chuang YC; Su YC; Liu WC; Hung CC; Chang SC
PLoS One; 2016; 11(12):e0169228. PubMed ID: 28033344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
